1-[(4-methoxyphenyl)methyl]piperidine-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[(4-methoxyphenyl)methyl]piperidine-4-carboxylic acid
• 英文别名: 1-(4-methoxybenzyl)piperidine-4-carboxylic acid；1-[(4-Methoxyphenyl)methyl]piperidin-1-ium-4-carboxylate
• 化学式: C₁₄H₁₉NO₃
• mdl: MFCD03371460
• 分子量: 249.31
• InChiKey: ZSAWCFNPIWERET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[(4-methoxyphenyl)methyl]piperidine-4-carboxylic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity

  摘要：

  This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.

  DOI：

  10.1248/cpb.c20-00015
• 作为产物：
  描述：

  ethyl 1-(4-methoxybenzyl)-4-piperidinecarboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 72.0h， 以1.2 g的产率得到1-[(4-methoxyphenyl)methyl]piperidine-4-carboxylic acid
  参考文献：
  名称：

  Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity

  摘要：

  This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.

  DOI：

  10.1248/cpb.c20-00015

文献信息

• Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers
  作者：Iris L.K. Wong、Xing-kai Wang、Zhen Liu、Wenqin Sun、Fu-xing Li、Bao-chao Wang、Peng Li、Sheng-biao Wan、Larry M.C. Chow

  DOI：10.1016/j.ejmech.2021.113795

  日期：2021.12

  Previous synthetic methylated epigallocatechin (EGC) possessed promising P-gp modulating activity. In order to further improve the potency, we have synthesized some novel stereoisomers of methylated epigallocatechin (EGC) and gallocatechin (GC) as well as epicatechin (EC) and catechin (C). The (2R, 3S)-trans-methylated C derivative 25 and the (2R, 3R)-cis-methylated EC derivative 31, both containing

  P-糖蛋白（P-gp；ABCB1）介导的药物外流导致癌症的多药耐药性。以前的合成甲基化表没食子儿茶素 (EGC) 具有有希望的 P-gp 调节活性。为了进一步提高效力，我们合成了甲基化表没食子儿茶素 (EGC) 和没食子儿茶素 (GC) 以及表儿茶素 (EC) 和儿茶素 (C) 的一些新型立体异构体。(2R, 3S)-转甲基化 C 衍生物25和 (2R, 3R)-顺式-甲基化 EC 衍生物31均在环 B 处含有二甲氧基化，在环 D 处含有三甲氧基化，并且在环 D 和 C3 之间含有氧羰基苯基氨基甲酰基接头，用 EC 50最有效地逆转 P-gp 介导的耐药性范围从 32 nM 到 93 nM。它们对成纤维细胞无毒，IC 50  > 100 μM。它们可以抑制 P-gp 介导的药物流出并将细胞内药物浓度恢复到细胞毒性水平。它们不会下调表面 P-gp 蛋白水平以增强药物保留。它们对 P-gp 具有特异性，对
• [EN] CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS<br/>[FR] DERIVES CARBAMOYLOXY DE MUTILINE ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTERIENS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997025309A1

  公开（公告）日：1997-07-17

  (EN) Derivatives of mutiline of formula (1A) and pharmaceutically acceptable salts and derivatives thereof, in which R1 is ethyl or vinyl, Y is a carbamoyloxy group, in which the N-atom is unsubstituted, or mono- or di-substituted, are useful in the treatment of bacterial infections.(FR) Dérivés de mutiline représentés par la formule (1A), ainsi que leurs sels et dérivés pharmaceutiquement acceptables, dans laquelle R1 représente éthyle ou vinyle, Y représente un groupe carbamoyloxy, dans lequel l'atome N est non substitué, ou mono ou di-substitué. Ces composés sont utiles dans le traitement d'infections bactériennes.

  (中文) 公式（1A）的多滤青霉素衍生物及其药学上可接受的盐和衍生物，在其中R1为乙基或乙烯基，Y为羰基氧基团，在其中N原子未被取代或被单取代或双取代，可用于治疗细菌感染。
• CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0874809A1

  公开（公告）日：1998-11-04
• US6020368A
  申请人：——

  公开号：US6020368A

  公开（公告）日：2000-02-01
• US6239175B1
  申请人：——

  公开号：US6239175B1

  公开（公告）日：2001-05-29